[
    [
        {
            "time": "",
            "orginal_text": "国际医药巨头即将登陆A股 药明康德引领国内CRO风潮",
            "features": {
                "keywords": [
                    "药明康德",
                    "CRO",
                    "A股",
                    "医药巨头"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CRO行业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "国际医药巨头即将登陆A股 药明康德引领国内CRO风潮",
            "scores": {
                "News_content": "国际医药巨头即将登陆A股 药明康德引领国内CRO风潮",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "药明康德顶格申购需配市值31万 一签或至少获利4万 挣钱效应凸显",
            "features": {
                "keywords": [
                    "药明康德",
                    "申购",
                    "市值",
                    "获利"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "资本市场"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "药明康德顶格申购需配市值31万 一签或至少获利4万 挣钱效应凸显",
            "scores": {
                "News_content": "药明康德顶格申购需配市值31万 一签或至少获利4万 挣钱效应凸显",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "药研独角兽药明康德的过人之处",
            "features": {
                "keywords": [
                    "药明康德",
                    "独角兽",
                    "过人之处"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "研发"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "药研独角兽药明康德的过人之处",
            "scores": {
                "News_content": "药研独角兽药明康德的过人之处",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "有鱼有研究 药明康德是如何赋能中国创新？",
            "features": {
                "keywords": [
                    "药明康德",
                    "赋能",
                    "中国创新"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "创新"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "有鱼有研究 药明康德是如何赋能中国创新？",
            "scores": {
                "News_content": "有鱼有研究 药明康德是如何赋能中国创新？",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "orginal_text": "CRO领军企业药明康德即将登陆A股 CRO行业带来发展契机",
            "features": {
                "keywords": [
                    "药明康德",
                    "CRO",
                    "A股",
                    "发展契机"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CRO行业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "CRO领军企业药明康德即将登陆A股 CRO行业带来发展契机",
            "scores": {
                "News_content": "CRO领军企业药明康德即将登陆A股 CRO行业带来发展契机",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "药明康德:CRO龙头回归,医药独角兽浪潮已起",
            "features": {
                "keywords": [
                    "药明康德",
                    "CRO",
                    "龙头",
                    "独角兽"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CRO行业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "药明康德:CRO龙头回归,医药独角兽浪潮已起",
            "scores": {
                "News_content": "药明康德:CRO龙头回归,医药独角兽浪潮已起",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "药明康德新研发基地建成 进一步提升药物研发测试服务能力",
            "features": {
                "keywords": [
                    "药明康德",
                    "研发基地",
                    "服务能力"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "研发"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "药明康德新研发基地建成 进一步提升药物研发测试服务能力",
            "scores": {
                "News_content": "药明康德新研发基地建成 进一步提升药物研发测试服务能力",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]